Loading…

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors

FcγRs are key regulators of the immune response, capable of binding to the Fc portion of IgG Abs and manipulating the behavior of numerous cell types. Through a variety of receptors, isoforms, and cellular expression patterns, they are able to fine-tune and direct appropriate responses. Furthermore,...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of immunology (1950) 2015-12, Vol.195 (11), p.5503-5516
Main Authors: Tutt, Alison L, James, Sonya, Laversin, Stéphanie A, Tipton, Thomas R W, Ashton-Key, Margaret, French, Ruth R, Hussain, Khiyam, Vaughan, Andrew T, Dou, Lang, Earley, Alexander, Dahal, Lekh N, Lu, Chen, Dunscombe, Melanie, Chan, H T Claude, Penfold, Christine A, Kim, Jinny H, Potter, Elizabeth A, Mockridge, C Ian, Roghanian, Ali, Oldham, Robert J, Cox, Kerry L, Lim, Sean H, Teige, Ingrid, Frendéus, Bjorn, Glennie, Martin J, Beers, Stephen A, Cragg, Mark S
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:FcγRs are key regulators of the immune response, capable of binding to the Fc portion of IgG Abs and manipulating the behavior of numerous cell types. Through a variety of receptors, isoforms, and cellular expression patterns, they are able to fine-tune and direct appropriate responses. Furthermore, they are key determinants of mAb immunotherapy, with mAb isotype and FcγR interaction governing therapeutic efficacy. Critical to understanding the biology of this complex family of receptors are reagents that are robust and highly specific for each receptor. In this study, we describe the development and characterization of mAb panels specific for both mouse and human FcγR for use in flow cytometry, immunofluorescence, and immunocytochemistry. We highlight key differences in expression between the two species and also patterns of expression that will likely impact on immunotherapeutic efficacy and translation of therapeutic agents from mouse to clinic.
ISSN:0022-1767
1550-6606
DOI:10.4049/jimmunol.1402988